Essentialis reports DCCR data in hypertriglyceridemia

Essentialis Inc. (San Diego, Calif.) reported data from a Phase IIb trial in 44 non-diabetics with fasting triglyceride levels of at least 500 mg/dL evaluating diazoxide choline controlled release ( DCCR) in combination with a statin or with fenofibrate.

In combination with Lipitor atorvastatin, DCCR led to placebo-adjusted median reductions from baseline to week 18 of 28% in triglycerides and 16% in non-HDL-C, as well as an increase of 11% in HDL-C. Essentialis said the reduction in triglycerides, the primary endpoint, was significant at days 14, 28 and 56 (p=0.04, p=0.02 and p=0.003, respectively). In combination with Trilipix fenofibric acid, DCCR led to median reductions from baseline to week 18 of 78% in triglycerides and 34% in non-HDL-C, as well as an increase of 38% in HDL-C. ...